Kristian Humer - 22 Jan 2025 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: FHTX
Reported as of: 22 Jan 2025
Net transaction value: +$524,400
SEC form: 4
Accepted by SEC: 24 Jan 2025, 16:15:38 UTC
Prior SEC filing: 13 Jun 2024
Next SEC filing: 23 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael LaCascia, Attorney-in-Fact for Kristian F. Humer

Key filing fact

Kristian Humer filed Form 4 for Foghorn Therapeutics Inc. (FHTX) on 24 Jan 2025.

Key facts

This page summarizes Kristian Humer's Form 4 filing for Foghorn Therapeutics Inc. (FHTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jan 2025, 16:15.

Change

Previous filing in this sequence was filed on 13 Jun 2024.
Current net transaction value: +$524,400.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FHTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $524,400
Shares: +120,000
Change %
Price: $4.37
Shares after: 120,000
Date: 22 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $4.37
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.